CDKN2A and acute lymphoblastic leukemia: There is evidence that the variant p16INK4A (p.148T) is preferentially retained in the nucleus, compromising its ability to inhibit CDK4 and CDK6 in the cytoplasm [15] and favoring proliferation, and therefore contributing to the association with ALL risk.